Vanzacaftor / tezacaftor / deutivacaftor · Alyftrek

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Cystic Fibrosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (1)
EU
  • Cystic fibrosis in people aged 6 years and older with at least one non-Class I CFTR mutation
Product first approved 2025EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Cystic Fibrosis
NCT05422222 · Vertex Pharmaceuticals Incorporated
2022-06-21 – 2030-06-30 · Cystic Fibrosis
What this study did
NCT05844449 · Vertex Pharmaceuticals Incorporated
2023-08-11 – 2029-07-30 · Cystic Fibrosis
What this study did
NCT05444257 · Vertex Pharmaceuticals Incorporated
2022-11-08 – 2026-10-30 · Cystic Fibrosis
What this study did
Phase 1 (5)
Cystic Fibrosis
NCT07349394 · Vertex Pharmaceuticals Incorporated
2026-01-12 – 2026-03-12 · Cystic Fibrosis
What this study did
NCT06299709 · Vertex Pharmaceuticals Incorporated
2024-03-13 – 2024-05-23 · Cystic Fibrosis
What this study did
NCT06299696 · Vertex Pharmaceuticals Incorporated
2024-03-26 – 2024-04-16 · Cystic Fibrosis
What this study did
NCT05535959 · Vertex Pharmaceuticals Incorporated
2022-09-15 – 2022-11-09 · Cystic Fibrosis
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Cystic Fibrosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Vanzacaftor / Tezacaftor / Deutivacaftor (Alyftrek): this drugApprovedSmall moleculeCFTRReliable signalNo reviewed efficacy summary in this indication
Elexacaftor / Tezacaftor / Ivacaftor (Trikafta)ApprovedSmall moleculeCFTR, CFTRReliable signal
NCT03525444: Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results).
NCT03525548: Absolute change in ppFEV1 from baseline at Week 4 vs tezacaftor/ivacaftor: +10.4 vs +0.4; treatment difference 10.0 percentage points (95% CI 7.4 to 12.6), P<0.0001 (TRIKAFTA label section 14.1; CT.gov posted results).
Ivacaftor (Kalydeco)ApprovedSmall moleculeCFTRPartial signal
NCT00909727: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1)
NCT00909532: Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo -0.2 percent of predicted volume (L) (Standard Error 0.7) | 150 mg Ivacaftor q12h 10.4 percent of predicted volume (L) (Standard Error 0.7)
Lumacaftor (Orkambi)ApprovedSmall moleculeCFTRReliable signalNo reviewed efficacy summary in this indication
Tezacaftor / Ivacaftor (Symdeko)ApprovedSmall moleculeCFTRnot yet gradedNo reviewed efficacy summary in this indication
KB407Phase 1Gene therapy / editingCFTR (gene replacement)not yet gradedNo reviewed efficacy summary in this indication
VX-828Phase 1Small moleculeCFTRnot yet gradedNo reviewed efficacy summary in this indication
LuvomeranDiscontinuedRNA / oligonucleotideCFTR (mRNA replacement)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Alyftrek (Vanzacaftor / tezacaftor / deutivacaftor) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
July 2029 (1)
Phase 3Cystic FibrosisEnrolling by invitation
Est. primary completion 2029-07-30 · NCT05844449 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 3Cystic FibrosisActive not recruiting
Est. primary completion 2030-06-30 · NCT05422222 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 June 2026Topline resultPhase 3 ALYFTREK data in children ages 2 to 5 with CF
2 January 2025FDA action datePDUFA target action date set
US, FDA · Source ↗
2 July 2024Filing acceptedFDA accepts NDA for vanzacaftor/tezacaftor/deutivacaftor
US, FDA · Source ↗
2 July 2024Priority reviewPriority review for vanza triple
US, FDA · Source ↗